Edition:
United Kingdom

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,940JPY
21 Nov 2018
Change (% chg)

¥58 (+2.01%)
Prev Close
¥2,882
Open
¥2,866
Day's High
¥2,958
Day's Low
¥2,854
Volume
1,307,900
Avg. Vol
1,345,585
52-wk High
¥3,035
52-wk Low
¥1,454

Latest Key Developments (Source: Significant Developments)

FDA Issues CRL For New Drug Application For Dasotraline For The Treatment Of Adhd
Friday, 31 Aug 2018 

Aug 31 (Reuters) - SUNOVION PHARMACEUTICALS ::FDA ISSUES A COMPLETE RESPONSE LETTER FOR NEW DRUG APPLICATION FOR DASOTRALINE FOR THE TREATMENT OF ADHD.SUNOVION PHARMACEUTICALS SAYS UPON COMPLETION OF REVIEW, FDA DETERMINED THEY CANNOT APPROVE DASOTRALINE NDA FOR TREATMENT OF ADHD IN CURRENT FORM.SUNOVION PHARMACEUTICALS SAYS PLANS TO MEET WITH FDA TO DISCUSS COMMENTS AND DETERMINE NEXT STEPS.SUNOVION PHARMACEUTICALS - FDA INDICATED ADDITIONAL DATA NEEDED TO FURTHER EVALUATE EFFICACY AND TOLERABILITY OF DASOTRALINE FOR TREATMENT OF ADHD.  Full Article

Sumitomo Dainippon Pharma Signed A 5-Year Agreement To Provide Enterprise-Wide Access To Newest Solution In Scifinder Family, Scifinder
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::CAS - SUMITOMO DAINIPPON PHARMA SIGNED A 5-YEAR AGREEMENT TO PROVIDE ENTERPRISE-WIDE ACCESS TO NEWEST SOLUTION IN SCIFINDER FAMILY, SCIFINDER.  Full Article

Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Carna Biosciences Inc <4572.T>:Says it and Sumitomo Dainippon Pharma Co Ltd <<<4506.T>>> , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent.  Full Article

Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - POXEL SA ::POXEL AND SUMITOMO DAINIPPON PHARMA <<<4506.T>>> ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN.JAPANESE NEW DRUG APPLICATION SUBMISSION FOR IMEGLIMIN TARGETED IN 2020.  Full Article

Sumitomo Dainippon Pharma says result of early-retirement program
Monday, 25 Dec 2017 

Dec 25 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T> ::Says 86 employees took up the offer of the early-retirement program announced on Sept. 27.Effective date of retirement is March 31, 2018.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Wednesday, 6 Dec 2017 

Dec 5 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.SUNOVION EXPECTS LONHALA MAGNAIR TO BE AVAILABLE IN U.S. PHARMACIES IN EARLY 2018.SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Monday, 30 Oct 2017 

Oct 30 (Reuters) - POXEL SA ::SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES.‍POXEL AND SUMITOMO DAINIPPON PHARMA TO JOINTLY DEVELOP IMEGLIMIN FOR TREATMENT OF TYPE 2 DIABETES IN JAPAN,​.‍SUMITOMO DAINIPPON PHARMA ASSUMES PHASE 3 AND COMMERCIALIZATION COSTS​.‍POXEL RECEIVES AN UPFRONT PAYMENT OF ¥4.75 BILLION (APPROXIMATELY EUR 36 MILLION, $42 MILLION)​.‍SUMITOMO DAINIPPON PHARMA SOLELY RESPONSIBLE FOR IMEGLIMIN IN CHINA, SOUTH KOREA, TAIWAN AND 9 OTHER SOUTHEAST ASIAN COUNTRIES​.‍PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN ON TRACK TO BE INITIATED IN Q4 OF CY 2017​.‍RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO ¥29.25 BILLION​.  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

Japan scientists to use "reprogrammed" stem cells to fight Parkinson's

TOKYO, July 30 Japanese scientists said on Monday they will start clinical trials next month on a treatment for Parkinson's disease, transplanting "reprogrammed" stem cells into brains, seeking a breakthrough in treating the neurodegenerative disorder.